This presentation, led by Dr. Donald Zoz MD, senior clinical program leader at Boehringer Ingelheim, provides some insight into FIBRONEER-IPF, a Phase 3 Clinical Trial.
The goal of FIBRONEER-IPF Phase 3 Clinical Trial is to evaluate the efficacy, safety, and tolerability of the compound BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF).
For more information on FIBRONEER-IPF, visit clinicaltrials.gov or contact Boehringer Ingelheim’s Clinical Trials Support Line at 1-833-602-2368.
Additional pulmonary fibrosis clinical trial resources can be found at cpff.ca/research-and-healthca....